Reilly Financial Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Reilly Financial Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,000	Closed	-$9K	–	1098
2017 Q4	$9K	Hold	2,000	–	–	﹤0.01%	688
2017 Q3	$3K	Hold	2,000	–	–	﹤0.01%	873
2017 Q2	$3K	Hold	2,000	–	–	﹤0.01%	858
2017 Q1	$5K	Hold	2,000	–	–	﹤0.01%	760
2016 Q4	$5K	Hold	2,000	–	–	﹤0.01%	687
2016 Q3	$6K	Hold	2,000	–	–	﹤0.01%	627
2016 Q2	$6K	Hold	2,000	–	–	﹤0.01%	586
2016 Q1	$6K	Hold	2,000	–	–	﹤0.01%	886
2015 Q4	$8K	Hold	2,000	–	–	﹤0.01%	848
2015 Q3	$9K	Buy	+2,000	New	+$10.5K	﹤0.01%	822

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Reilly Financial Advisors's ECYT Position: Q1 2018 in Review

Reilly Financial Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 2,000 shares — an estimated $9K sold.

Reilly Financial Advisors first reported a position in ECYT in Q3 2015 and held it in 10 quarters. The position peaked at $9K in Q4 2017. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Reilly Financial Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Reilly Financial Advisors sold 2,000 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $9K.
Reilly Financial Advisors first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 10 quarters.
Reilly Financial Advisors's Endocyte, Inc. Common Stock position peaked at $9K in Q4 2017.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Reilly Financial Advisors's 13F filing for Q1 2018, filed 30 Apr 2018.